Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion

Session Moderator(s)

• 

  Cathy Eng, MD, FACP, FASCO

  Vanderbilt-Ingram Cancer Center
  MD Anderson Cancer Center
• 

  Sonia Kupfer, MD

  University of Chicago

Panelist(s)

• 

  Namrata (Neena) Vijayvergia, MD, FACP

  Fox Chase Cancer Center
• 

  Smitha Krishnamurthi, MD

  Department of Hematology and Oncology at Cleveland Clinic